In our tibial model of bone metastasis with Ac-KLF5 expression, inhibition of CXCR4 with plerixafor (i.e., AMD3100), an FDA-approved drug for non-Hodgkin lymphoma and multiple myeloma, not only suppressed bone metastatic growth but also sensitized bone metastases to the therapeutic effect of docetaxel (Fig. 8). Here, KLF5 is linked to plasma cell myeloma.